Stock AnalizRelay Therapeutics, Inc. RLAY
Biotechnology: Biological Products (No Diagnostic Substances) · IPO 2020 · data as of November 13, 2026
Relay Therapeutics, Inc. (RLAY) is a healthcare company listed in the US with a market value of about $4.0B. In the twelve months to September 30, 2026 it had revenue of $10M and net income of -$294M, a net margin of -2837.0%.
Its overall Stock Analiz score is 1.2 out of 5 (weak). The strongest part is future growth (4/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of -29% a year, a 5-year average ROIC of -33%.
Score: 1.2 / 5
Checks passed
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
- 5-year revenue growth above 8% a year
Valuation
Growth and quality
Financials, last 7 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $10M | $15M | $10M | $26M | $1M | $3M | $83M | — |
| Net income | -$294M | -$276M | -$338M | -$342M | -$291M | -$364M | -$52M | -$75M |
| Free cash flow | -$214M | -$236M | -$251M | -$304M | -$239M | -$78M | -$104M | -$74M |
| EPS (diluted) | $-1.50 | $-1.61 | $-2.36 | $-2.79 | $-2.59 | $-3.82 | $-5.40 | $-21.82 |
| Net margin | -2837.0% | -1800.6% | -3374.7% | -1338.7% | -21036.1% | -12012.9% | -63.4% | — |
| ROIC | — | -39.9% | -35.6% | -36.6% | -23.5% | -31.3% | -5.6% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 12 analysts is $28.25, 56% above the current price; targets range from $25.00 to $32.00; the consensus rating is “Strong buy”; expected EPS is $-1.56 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Relay Therapeutics pay a dividend?
Not currently.
Is Relay Therapeutics a good stock to buy?
We do not give buy or sell advice. Relay Therapeutics scores 1.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.